Definium's LSD-based anxiety treatment succeeds in third Phase 3 trial
Definium Therapeutics announced positive results from its third Phase 3 study of oral LSD candidate DT120 for anxiety disorders. The company plans to submit an FDA application based on these data. This is the latest in a series of successful late-stage readouts this year.
Definium Therapeutics has reported positive outcomes from its third consecutive Phase 3 clinical trial evaluating DT120, an oral LSD formulation designed to address anxiety disorders. The company indicated that this latest dataset will form the basis of a forthcoming application to U.S. regulators. The announcement continues a notable pattern of successful late-stage results for the firm throughout the current year.
The development places Definium among a growing number of companies exploring psychedelic-derived compounds for psychiatric conditions. With multiple Phase 3 successes now accumulated, the candidate appears positioned for regulatory review, though the specific patient populations, dosing protocols, and efficacy measurements from the trials were not detailed in the announcement.
If approved, this treatment could offer a new option for the millions of individuals with anxiety disorders who do not respond adequately to existing therapies. The oral format may improve accessibility compared to other psychedelic treatments requiring clinical supervision. However, broader adoption may depend on how regulators, insurers, and clinicians weigh the therapy's risks against its benefits, and on whether patients are willing to consider a treatment with psychedelic origins.